Targeting of BMI-1 represents a promising novel therapeutic strategy among these evolving arsenals of specific inhibitors due to its universal expression pattern in MM and its impact on the myeloma microenvironment. This evidence concerns the gene BMI1 and Miyoshi myopathy.